 | |
| Clinical data | |
|---|---|
| Other names | C-CAM; CCAM; NIH-10443 |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C29H29ClN2O4 |
| Molar mass | 505.01 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Clocinnamox (CCAM orC-CAM; developmental code nameNIH-10443) is aselective andirreversibleantagonist of theμ-opioid receptor.[1][2] Closely related compounds includemethocinnamox (MCAM) andmethoclocinnamox (MCCAM).[1][3][4][5] They werederived viastructural modification ofbuprenorphine.[6][5] Clocinnamox was first described in thescientific literature by 1992.[7]
Given the advantages of buprenorphine as a treatment for opioid use disorder, additional compounds related to buprenorphine were synthesized in an attempt to reduce its adverse effects (Broadbear et al. 2000). These efforts resulted in the discovery of the mu opioid receptor antagonist methocinnamox (MCAM). Like buprenorphine, MCAM binds pseudoirreversibly to mu opioid receptors; however, it does not appear to produce agonist effects at mu opioid receptors under any conditions. Instead, MCAM produces long-lasting antagonism at mu opioid receptors, as evidenced by attenuation of the antinociceptive effects of morphine in rodents, with the morphine dose-effect curve shifted up to hundredfold rightward (Peckham et al. 2005) and antagonist effects evident for at least 2 days after administration (Broadbear et al. 2000).
